Protagonist Therapeutics (PTGX) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Protagonist Therapeutics (PTGX) over the last 5 years, with Q3 2025 value amounting to -$0.62.
- Protagonist Therapeutics' EPS (Weighted Average and Diluted) fell 1481.48% to -$0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.65, marking a year-over-year decrease of 7627.74%. This contributed to the annual value of $4.23 for FY2024, which is 40421.62% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' EPS (Weighted Average and Diluted) is -$0.62, which was down 1481.48% from -$0.55 recorded in Q2 2025.
- Protagonist Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $3.26 for Q1 2024, and its period low was -$0.84 during Q2 2022.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.58 (2023), whereas its average is -$0.2.
- In the last 5 years, Protagonist Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 58656.72% in 2024 and then crashed by 10582.82% in 2025.
- Protagonist Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.77 in 2021, then increased by 9.09% to -$0.7 in 2022, then skyrocketed by 174.29% to $0.52 in 2023, then skyrocketed by 289.1% to $2.02 in 2024, then crashed by 130.64% to -$0.62 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.62 in Q3 2025, compared to -$0.55 in Q2 2025 and -$0.19 in Q1 2025.